Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 66

Sort by

Sort Order Select

Journal Articles

Impact of immunochemotherapy regimens on outcomes of patients with primary mediastinal B-cell lymphoma in the IELSG37 trial

Blood (2025) 146 (23): 2758–2764.

https://doi.org/10.1182/blood.2025028823

Published: 2025

Includes: Supplemental data

Journal Articles

Interim analysis of PRO-MIND: Consistent quality of life in elderly patients with R/R DLBCL receiving tafasitamab and lenalidomide

Pier Luigi Zinzani, Maria Cox, Flaminia Bellisario, Andrea Bernardelli, Maurizio Musso, Guido Gini, Alice Di Rocco, Eliana Liardo, Enrico Derenzini, Elsa Pennese, Nicola Battaglia, Mario Lapecorella, Antonio Pinto

Blood (2025) 146 (Supplement 1): 7248.

https://doi.org/10.1182/blood-2025-7248

Published: 2025

Journal Articles

Anti-CD19 chimeric antigen receptor T-cells therapy (CAR-T) is effective in secondary cns lymphoma (SCNSL) refractory to high-dose methotrexate (HDMTX)-based chemotherapy

Blood (2025) 146 (Supplement 1): 7241.

https://doi.org/10.1182/blood-2025-7241

Published: 2025

Journal Articles

Predicting CAR T-cell therapy outcomes in large B-cell lymphoma using pre-infusion clinical and inflammatory markers: A machine learning approach with explainable artificial intelligence

Blood (2025) 146 (Supplement 1): 2569.

https://doi.org/10.1182/blood-2025-2569

Published: 2025

Journal Articles

Hbc-positive status for hepatis B virus does not affect CAR-T cell outcomes in lymphoma: Results from the CART-SIE study

Blood (2025) 146 (Supplement 1): 7636.

https://doi.org/10.1182/blood-2025-7636

Published: 2025

Journal Articles

Ibrutinib plus R-CHOP followed by maintenance in untreated ABC-DLBCL patients with IPI ≥2: A first analysis of phase II Study FIL_RI-CHOP

Blood (2025) 146 (Supplement 1): 55.

https://doi.org/10.1182/blood-2025-55

Published: 2025

Journal Articles

Checkpoint inhibitors exposure does not affect survival and safety in PMBCL patients receiving CAR T-cells therapy: An analysis of the italian CART-SIE study

Blood (2025) 146 (Supplement 1): 5502.

https://doi.org/10.1182/blood-2025-5502

Published: 2025

Journal Articles

Cytomegalovirus (CMV) reactivation negatively impacts survival after CAR T-cell therapy in lymphoma patients: Results from the CART-SIE study

Blood (2025) 146 (Supplement 1): 3722.

https://doi.org/10.1182/blood-2025-3722

Published: 2025

Journal Articles

Anti-CD19 CAR T cells therapy can overcome the prognostic impact of CD5-positivity in patients with diffuse large B cell lymphomas: Results from the multicenter prospective CAR-T SIE study

Blood (2025) 146 (Supplement 1): 3721.

https://doi.org/10.1182/blood-2025-3721

Published: 2025

Journal Articles

Health-related quality of life trajectories of patients with aggressive B-cell lymphomas treated with CAR T-cell therapy: Results from a prospective observational study

Blood (2025) 146 (Supplement 1): 6279.

https://doi.org/10.1182/blood-2025-6279

Published: 2025

Journal Articles

The prognostic value of patient-reported fatigue for survival in patients with aggressive B-cell lymphomas treated with CAR T-cell therapy

Blood (2025) 146 (Supplement 1): 6278.

https://doi.org/10.1182/blood-2025-6278

Published: 2025

Journal Articles

Factors Predicting Short-Term Symptom Burden in Patients with Aggressive B-Cell Lymphomas Treated with CAR T-Cell Therapy: A Real-World Study By the Gimema

Blood (2024) 144 (Supplement 1): 7823.

https://doi.org/10.1182/blood-2024-199498

Published: 2024

Journal Articles

TP53 , CD36 Mutations and CDKN2A Loss Predict Poor Outcome in Mantle Cell Lymphoma: Molecular Analysis of the FIL V-Rbac Phase 2 Trial

Blood (2024) 144 (Supplement 1): 1577.

https://doi.org/10.1182/blood-2024-198076

Published: 2024

Journal Articles

A SWOT-Consensus for CAR-T in Follicular Lymphoma: Fine Tuning of Patient Journey and Selection

Monia Marchetti, Paolo Corradini, Luca Arcaini, Stefania Bramanti, Alice Di Rocco, Marco Ladetto, Stefano Luminari, Luigi Rigacci, Pier Luigi Zinzani

Blood (2024) 144 (Supplement 1): 2269.

https://doi.org/10.1182/blood-2024-198647

Published: 2024

Journal Articles

Outcomes of CAR T-Cells Therapy in High-Grade B-Cell Lymphomas Compared to Diffuse Large B-Cell Lymphomas: A Weighted Comparison Analysis from CAR-T SIE Study

Blood (2024) 144 (Supplement 1): 3131.

https://doi.org/10.1182/blood-2024-199720

Published: 2024

Journal Articles

PET-Based Prognostic Stratification in Primary Mediastinal B-Cell Lymphoma Using the SUV≥4 Segmentation Threshold: A Comparative Analysis of Contouring Methods in the IELSG37 Trial Cohort

Luca Ceriani, Lisa Milan, Maria Cristina Pirosa, Alice Di Rocco, Teresa Ruberto, Luciano Cascione, Peter Johnson, Andrew J. Davies, Maurizio Martelli, Emanuele Zucca

Blood (2024) 144 (Supplement 1): 1712.

https://doi.org/10.1182/blood-2024-206784

Published: 2024

Journal Articles

Outcomes of younger patients with mantle cell lymphoma experiencing late relapse (>24 months): the LATE-POD study

Blood (2024) 144 (9): 1001–1009.

https://doi.org/10.1182/blood.2023023525

Published: 2024

Includes: Supplemental data

Journal Articles

Rituximab, Bendamustine and Cytarabine Followed By Venetoclax (V-RBAC) in High-Risk Older Patients with Mantle Cell Lymphoma: A Phase 2 Study By the Fondazione Italiana Linfomi (FIL)

Blood (2023) 142 (Supplement 1): 737.

https://doi.org/10.1182/blood-2023-179169

Published: 2023

Journal Articles

Patients' Perception of Usability and Utility of a Digital Health Tool for Electronic Patient-Reported Outcomes Monitoring in Real-Life Hematology Practice: Evidence from the Gimema-Alliance Platform

Blood (2023) 142 (Supplement 1): 3714.

https://doi.org/10.1182/blood-2023-180574

Published: 2023

Journal Articles

Positron Emission Tomography Evaluation in Relapsed/Refractory B-Cell Lymphoma Patients Treated with Anti-19 Chimeric Antigen Receptor (CAR) T-Cells in the CART-SIE Observational Study

Blood (2023) 142 (Supplement 1): 3517.

https://doi.org/10.1182/blood-2023-184614

Published: 2023

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Impact of immunochemotherapy regimens on outcomes of patients with primary mediastinal B-cell lymphoma in the IELSG37 trial

Interim analysis of PRO-MIND: Consistent quality of life in elderly patients with R/R DLBCL receiving tafasitamab and lenalidomide

Anti-CD19 chimeric antigen receptor T-cells therapy (CAR-T) is effective in secondary cns lymphoma (SCNSL) refractory to high-dose methotrexate (HDMTX)-based chemotherapy

Predicting CAR T-cell therapy outcomes in large B-cell lymphoma using pre-infusion clinical and inflammatory markers: A machine learning approach with explainable artificial intelligence

Hbc-positive status for hepatis B virus does not affect CAR-T cell outcomes in lymphoma: Results from the CART-SIE study

Ibrutinib plus R-CHOP followed by maintenance in untreated ABC-DLBCL patients with IPI ≥2: A first analysis of phase II Study FIL_RI-CHOP

Checkpoint inhibitors exposure does not affect survival and safety in PMBCL patients receiving CAR T-cells therapy: An analysis of the italian CART-SIE study

Cytomegalovirus (CMV) reactivation negatively impacts survival after CAR T-cell therapy in lymphoma patients: Results from the CART-SIE study

Anti-CD19 CAR T cells therapy can overcome the prognostic impact of CD5-positivity in patients with diffuse large B cell lymphomas: Results from the multicenter prospective CAR-T SIE study

Health-related quality of life trajectories of patients with aggressive B-cell lymphomas treated with CAR T-cell therapy: Results from a prospective observational study

The prognostic value of patient-reported fatigue for survival in patients with aggressive B-cell lymphomas treated with CAR T-cell therapy

Factors Predicting Short-Term Symptom Burden in Patients with Aggressive B-Cell Lymphomas Treated with CAR T-Cell Therapy: A Real-World Study By the Gimema

TP53 , CD36 Mutations and CDKN2A Loss Predict Poor Outcome in Mantle Cell Lymphoma: Molecular Analysis of the FIL V-Rbac Phase 2 Trial

A SWOT-Consensus for CAR-T in Follicular Lymphoma: Fine Tuning of Patient Journey and Selection

Outcomes of CAR T-Cells Therapy in High-Grade B-Cell Lymphomas Compared to Diffuse Large B-Cell Lymphomas: A Weighted Comparison Analysis from CAR-T SIE Study

PET-Based Prognostic Stratification in Primary Mediastinal B-Cell Lymphoma Using the SUV≥4 Segmentation Threshold: A Comparative Analysis of Contouring Methods in the IELSG37 Trial Cohort

Outcomes of younger patients with mantle cell lymphoma experiencing late relapse (>24 months): the LATE-POD study

Rituximab, Bendamustine and Cytarabine Followed By Venetoclax (V-RBAC) in High-Risk Older Patients with Mantle Cell Lymphoma: A Phase 2 Study By the Fondazione Italiana Linfomi (FIL)

Patients' Perception of Usability and Utility of a Digital Health Tool for Electronic Patient-Reported Outcomes Monitoring in Real-Life Hematology Practice: Evidence from the Gimema-Alliance Platform

Positron Emission Tomography Evaluation in Relapsed/Refractory B-Cell Lymphoma Patients Treated with Anti-19 Chimeric Antigen Receptor (CAR) T-Cells in the CART-SIE Observational Study

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only